Mangoceuticals, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Mangoceuticals, Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Tangible Assets Ratio: Of every $100 the company owns, $12 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles. Less tangible than almost all Healthcare companies in United States.
- Growth Efficiency Ratio: Sales grew 5,001% in 3 years, but profit fell: $4,170 less profit per $100 of extra sales. Lower than almost all Healthcare companies in United States.
- Shareholder Slice Ratio: Share count rose 1,456% in 3 years, so each share's slice of the company became smaller. Bigger rise in share count than 91% of Healthcare companies in United States.
Where $100 of sales goes
Latest year (Dec 2025). Taxes and other income are not shown, so the parts need not add up to 100.
Cash quality
Profit Cash Ratio
—Loss-making or profit too small
Over the last 3 years profit was a loss or under 2% of sales, so cash per 100 of profit is not meaningful.
Self-Funding Ratio
—Data incomplete
Cash Locked Ratio
—Data incomplete
Growth quality
Steadiness Ratio
1/3 · 1/3Sales grew in 1 of the last 3 years; profit grew in 1 of 3.
Less steady than 70% of Healthcare companies in United States.
Growth Efficiency Ratio
−$4,170Sales grew 5,001% in 3 years, but profit fell: $4,170 less profit per $100 of extra sales.
Lower than almost all Healthcare companies in United States.
Asset Productivity Ratio
+5001% / +1504%In 3 years sales changed by +5001% while total assets changed by +1504%. Sales grew faster than assets.
Balance-sheet strength
Debt Due Cover Ratio
-19.0×Operating cash was negative last year, while some debt falls due within a year.
Lower than 54% of Healthcare companies in United States.
Cash Cushion Ratio
+22%Cash, after subtracting all debt, equals 22% of its market value (net cash).
Higher than 64% of Healthcare companies in United States.
Tangible Assets Ratio
12%Of every $100 the company owns, $12 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles.
Less tangible than almost all Healthcare companies in United States.
Tangible Net Worth Ratio
6%Of every $100 of net worth, $6 is tangible; the rest is goodwill and other intangibles, often from buying other companies.
Less tangible than 71% of Healthcare companies in United States.
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (13)
Mangoceuticals, Inc. made a loss over the last year. Mangoceuticals, Inc. owes $0.12 for every $1 it owns. Mangoceuticals, Inc. made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
LossMangoceuticals, Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
0.41The share price is 0.41 times Mangoceuticals, Inc.'s book value per share, lower than 93% of Healthcare companies in United States.
Market cap
$5 MThe total market value of all of Mangoceuticals, Inc.'s shares at today's price (share price × number of shares), smaller than 93% of Healthcare companies in United States. PosiCap size class: Nano Cap.
Net worth (book value)
$13 MWhat Mangoceuticals, Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$0.56Net worth divided by the number of shares. The share price of $0.23 is 0.4 times this, which is the P/B above.
Return on equity (ROE)
-95.1%Mangoceuticals, Inc. lost 95.1% of its shareholders' money over the last year, lower than 69% of Healthcare companies in United States.
Owes vs Owns
0.12×Mangoceuticals, Inc. owes $0.12 for every $1 it owns (low), lower than 84% of Healthcare companies in United States.
Dividend yield
NoneMangoceuticals, Inc. does not currently pay a dividend.
Revenue growth
-26%Revenue fell 26% in the year to Dec 2025, and grew 271% a year on average over 3 years.
Profit growth
LossMangoceuticals, Inc. made a loss in each of the last two years.
Profit margin
-4526.8%Mangoceuticals, Inc. lost $4527 for every $100 of revenue.
Interest cover
Not coveredMangoceuticals, Inc.'s operating profit did not cover its interest costs in the year to Dec 2025.
Cash vs debt
Net cashMangoceuticals, Inc. held $1 M more cash than debt (net cash) at Dec 2025.
Questions
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Mangoceuticals, Inc.: $5 M ÷ $13 M (30 Jun 2026) = 0.4.
What is Mangoceuticals, Inc.'s return on equity?
Mangoceuticals, Inc. lost 95.1% of its shareholders' money over the last year, lower than 69% of Healthcare companies in United States.
How much does Mangoceuticals, Inc. owe compared with what it owns?
Mangoceuticals, Inc. owes $0.12 for every $1 it owns (low), lower than 84% of Healthcare companies in United States.
Does Mangoceuticals, Inc. pay a dividend?
No. Mangoceuticals, Inc. does not currently pay a dividend.
Is Mangoceuticals, Inc.'s revenue growing?
Revenue fell 26% in the year to Dec 2025, and grew 271% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.